MET skipping mutation, EGFR
|
|
- Christal Dean
- 6 years ago
- Views:
Transcription
1 New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain
2 Contents Background MET mutations causing exon 14 skipping Liquid biopsies Conclusions
3 Contents Background MET mutations causing exon 14 skipping Liquid biopsies Conclusions
4 NSCLC: emerging biomarkers in clinical research Emerging targeted agents for patients with genetic alterations Genetic alteration (i.e. driver event) High-level MET amplification or MET exon 14 skipping mutation RET rearrangements Available targeted agents with activity against driver event in lung cancer Crizotinib Cabozantinib Vandetanib HER2 mutations Trastuzumab (category 2B) Afatinib (category 2B) HER2, human epidermal growth factor receptor 2; MET, MET proto-oncogene, receptor tyrosine kinase; NCCN, National Comprehensive Cancer Network; NSCLC, non-small-cell lung cancer; RET, RET proto-oncogene. NCCN guidelines version NSCLC. Available from: Accessed: September 2017.
5 NSCLC: emerging biomarkers in clinical research ctdna H&E P40 TTF1 NSCLC- NOS x 1 x 1 x 1 H&E AC x 1 Lap B1 Diagnosis ALK translocation 720 ROS1 translocation PD-L1 expression EGFR mutation If EGFR/ALK/ROS1 negative Multiplexed genetic sequencing panels FISH IHC IHC or If Expert positive consensus opinion: in some clinical settings in which tissue is limited x and/or 10 (DNA) insufficient for molecular + testing, IHC FISH x 12 (RNA) physicians may in future consider T790M to testing use a cfdna assay for x 2 x 2 x 1 Progressed EGFR EGFR ctdna positive Multiplexed genetic If negative Expert sequencing consensus opinion: physicians may use cfdna PD-L1 expression panels methods to identify for EGFR T790M mutations in lung AC IHC patients with progression or acquired resistance to EGFR-TKIs Testing x10 (DNA) of the tumour sample will be in future recommended x 1 is recommended x12 (RNA) if the plasma result is negative Lap B2 Biomarkers 5% (real-time PCR) 30% (NGS) H&E x 1 AC, adenocarcinoma; ALK, anaplastic lymphoma kinase; cfdna, cell-free plasma DNA; ctdna, circulating tumour- DNA; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization; H&E, haematoxylin and eosin; IHC, immunohistochemistry; NGS, next-generation sequencing; NOS, not otherwise specified; PCR, polymerase chain reaction; PD-L1, programmed death-ligand 1; ROS1, ROS1 proto-oncogene receptor tyrosine kinase. Adapted from Conde E, et al. Clin Transl Oncol. 2013;15:503-8, following the 2016 revised molecular testing guideline for selection of lung cancer patients (CAP, IASLC, AMP, draft statements 2016).
6 Contents Background MET mutations causing exon 14 skipping Liquid biopsies Conclusions
7 MET mutations causing exon 14 skipping Distribution of genotypes among 933 patients with non-squamous NSCLC NSCLC (2.6%, 2.7%, 3%, 5.3%) KRAS (34%) EGFR (19%) No oncogenic mutation identified (30%) ALK (3.9%) BRAF (3.8%) MET exon 14 (3.0%) PIK3CA (2.9%) ERBB2 (2.5%) NRAS (1%) RET (1%) ROS1 (1%) AKT (< 1%) HRAS (< 1%) MAP2K1 (< 1%) Sarcomatoid variant, with AC morphology (5%, 22%, 32%) Always with MET overexpression (IHC) MET amplification in ~ 15 21% Concurrent amplifications MDM2 (~ 35%) CDK4 (~ 20%) AKT, AKT serine/threonine kinase 1; BRAF, B-Raf proto-oncogene; CDK4, cyclin-dependent kinase 4 gene; ERBB2, erb-b2 receptor tyrosine kinase 2; HRAS, HRas proto-oncogene; KRAS, Kirsten rat sarcoma viral oncogene homologue; MAP2K1, mitogen-activated protein kinase kinase 1; MDM2, murine double minute gene; NRAS, NRAS proto-oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha. Awad MM, et al. J Clin Oncol. 2016;34: Mengoli MC, et al. Clin Cancer Res. 2016:22; Saffroy R, et al. Oncotarget. 2017;8: Liu X, et al. J Clin Oncol. 2016;34: Schrock AB, et al. J Thorac Oncol. 2016;11: Tong JH, et al. Clin Cancer Res. 2016;22:
8 MET mutations causing exon 14 skipping Example of MET alterations Deletion at the splice acceptor site (~ 41%) g del49 g del28 g del26 g del20 g del28 g del30 g del27 Deletion at the splice donor site (~ 11%) g del25 g del24 g del12 g del14 Mutation at the splice donor site (~ 48%) g G>A g G>C g G>T g G>A g G>T g G>C g T>A g T>C g c.2888 TTAAGATCTGG Splice acceptor site 141 bases 47 AA Exon 14 g c.3028.cagaaggtata Splice donor site CBL, cobalamin. Amino acid sequence Regulatory sites: METex14 alterations, n (%) DLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPE PKC phospho site (S985) Caspase site (D1002) CBL docking site (Y1003) Base substitution splice donor 149 (49.1) Indel splice acceptor 100 (32.9) Indel splice donor 42 (13.8) Base substitution splice acceptor 4 (1.3) Base substitution noncoding adjacent spice acceptor 4 (1.3) Indel noncoding adjacent spice acceptor 3 (1.0) Whole exon 14 deletion 2 (0.7) Cortot AB, et al. J Natl Cancer Inst. 2017;109. Schrock AB, et al. J Thorac Oncol. 2016;11:
9 MET mutations causing exon 14 skipping HGF, hepatocyte growth factor; PKC, protein kinase C. Cortot AB, et al. J Natl Cancer Inst. 2017;109.
10 MET mutations causing exon 14 skipping RNA panel Fusion drivers (n = 23) For Research Use Only. Not for use in diagnostic procedures Data courtesy of López-Ríos, F.
11 Case 1. MET mutations enriched in pan-negative lung adenocarcinomas Female, 72 years old Lung AC, stage IV Data courtesy of López-Ríos, F.
12 Case 1. MET mutations enriched in pan-negative lung adenocarcinomas Oncomine focus assay CNV: MET (x5,09 copies); confirmed with FISH (ratio 5:40) MET exon 14 deletion [ skipping exon 14 MET, MET(Ex13) MET(Ex15)]; confirmed with RT-PCR FISH MET+ IHC MET+ CNV, copy number variation; NF1, neurofibromin 1; RIT1, Ras-like in all tissues; RT-PCR, reverse transcriptase-polymerase chain reaction. Collisson EA, et al. Nature. 2014;511: Data courtesy of López-Ríos, F.
13 Case 2. MET mutations not always MET-amplified Oncomine focus assay No CNV; confirmed with FISH (MET) MET exon 14 deletion [ skipping exon 14 MET, MET(Ex13) MET(Ex15)]; confirmed with RT-PCR IHC MET+ FISH MET Data courtesy of López-Ríos, F.
14 Contents Background MET mutations causing exon 14 skipping Liquid biopsies Conclusions
15 Liquid biopsies: analytical options Available technologies for genotyping of plasma cfdna Characteristic Variants potentially detected Quantitation Speed and complexity Allele-specific PCR Known recurring mutations Semiquantitative (against standard curve) Rapid, relatively easy to interpret PCR assays Emulsion PCR Known recurring mutations Absolute or relative quantitation, wide dynamic range Rapid, relatively easy to interpret Amplicon-based targeted NGS Any exonic mutations, copy number gains Quantitation of relative AF, but vulnerable to PCR amplification bias Potentially rapid, less complex bioinformatics NGS assays Capture-based targeted NGS Exonic mutations intromic gene fusions, copy number gains Quantitation of relative AF Potentially slower more complex bioinformatics AF, allele frequency.
16 Liquid biopsies: sensitivity and specificity Performance of four different plasma assays, using a tissue a test result as a non-reference standard, for detection of EGFR mutations from ctdna in a set of 38 plasma samples from the AURA clinical trial Exon 19 deletion qpcr ARMS-PCR ddpcr TM BEAMingdPCR Sensitivity, % (n/n) 86 (24/28) 82 (23/28) b 93 (26/28) Specificity, % (n/n) 100 (10/10) 100 (10/10) b 100 (10/10) Concordance, % b 95 L858R Sensitivity, % (n/n) 90 (9/10) 78 (7/9) 90 (9/10) 100 (10/10) Specificity, % (n/n) 100 (28/28) 100 (28/28) 100 (28/28) 93 (26/28) Concordance, % T790M Sensitivity, % (n/n) 41 (7/17) 29 (5/17) 71 (12/17) 71 (12/17) Specificity, % (n/n) 100 (6/6) 100 (6/6) 83 (5/6) 67 (4/6) Concordance, % a 24/38 samples were tested using local tissue assays and 14/38 samples were tested via central assays. b Comprehensive exon 19 deletion data not available. ARMS, amplification refractory mutation system; ddpcr Droplet Digital polymerase chain reaction; dpcr, digital polymerase chain reaction.
17 Liquid biopsies: sensitivity and specificity Concordance, sensitivity, specificity, PPV, and NPV of tissue and cfdna tests (n = 238) by EGFR mutation type Overall EGFR mutation-positive Exon 19 deletion L858R G719x L861Q Concordance, % Sensitivity, % Specificity, % PPV, % NPV, % Tissue-positive patients, n For Research Use Only. Not for use in diagnostic procedures NPV, negative predictive value; PPV, positive predictive value.
18 Promising technology for future use for liquid biopsies: NGS Assay Genes Selected SNV hotspots Oncomine lung cfdna assay ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and TP53 An example of our results Oncomine Lung cfdna Assay > 150 hotspots including EGFR: T790M, C797S, L848R, exon 19 del KRAS: G12X, G13X, Q61X BRAF: V600E ALK: exon PIK3CA: E545K, H1047R, E542K Position Allele Frequency LOD chr7: EGFR p.l747_p753s 32.33% 0.05% chr7: EGFR p.t790m 15.87% 0.10% chr7: EGFR p.c797s 15.29% 0.10% LOD (20 ng) 0.1% LOD, log odds ratio; TP53, tumour protein 53. For Research Use Only. Not for use in diagnostic procedures Data courtesy of López-Ríos, F.
19 Case 3. Importance of broad profiling 2014 Lung AC Male, 70 years old IHC TTF1+/P40 EGFR exon 19 deletion (real-time PCR) No ALK fusion Treated with 3rd-generation TKIs 2016 Soft-tissue metastasis 52 genes NGS panel EGFR exon 19 deletion confirmation No ALK fusion T790M mutation C797S mutation Controls Position Control type Control status Flags Accepted by A01:A02:A03 Mutant control Valid B01:B02:B03 Specimens Position D01:D02:D03 Run name: 07-FEB :16 EGFR P1 Negative control Sample ID Test result Mutation detected IHC TTF1+ For Research Use Only. Not for use in diagnostic procedures Valid Mutation result Flags Accepted by Exon 19 deletion Data courtesy of López-Ríos, F.
20 Case 3. Importance of broad profiling Case Tumour FFPE (NGS assay) Plasma Case Assay 1: NGS plasma panel Plasma Assay 2: PCR plasma T790M T790M T790M EGFR exon 19 deletion EGFR exon 19 deletion EGFR exon 19 deletion C797S C797S Not included in panel For Research Use Only. Not for use in diagnostic procedures Data courtesy of López-Ríos, F.
21 Promising technology for future use for liquid biopsies: NGS total NA Oncomine Lung cftna Assay ALK BRAF EGFR ERBB2 KRAS MAP2K1 MET NRAS PIK3CA RET ROS1 TP53 Enhanced content Amplicons: 58 Total genes: 12 Key hotspot mutations in 11 genes Increase in hotspot SNVs and indels Fusions (49) ALK, RET, ROS1 1% LOD CNV MET MET exon 14 skipping single library (DNA and RNA) SNV LOD down to 0.1% with 20 ng input SNV, single-nucleotide variants; TNA, total nucleic acid. For Research Use Only. Not for use in diagnostic procedures
22 Oncomine Lung cftna Assay: early experience Analysis of plasma samples from patients diagnosed with NSCLC and previously characterized by NGS (Oncomine TM Focus Assay) or FISH analysis (FFPE samples). Oncomine Lung cftna Assay Controls (n=4) run in parallel according to manufacturer s instructions. 1) Run performance OK: the assay works! For Research Use Only. Not for use in diagnostic procedures
23 Oncomine Lung cftna Assay: early experience 2) Analysis: A real sample FFPE tumor sample (FISH analysis) Plasma sample (Oncomine Lung cftna Assay) ALK positive For Research Use Only. Not for use in diagnostic procedures
24 Contents Background MET mutations causing exon 14 skipping Liquid biopsies Conclusions
25 Conclusions Broad profiling is recommended in NSCLC MET mutations causing exon 14 skipping is an emerging biomarker that can be detected with targeted NGS Using NGS in liquid biopsies allows for the detection of mutations, CNV, and rearrangements
26
27 Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or application of Thermo Fisher Scientific products presented by third parties during this seminar. Information and materials presented or provided by third parties are provided as-is and without warranty of any kind, including regarding intellectual property rights and reported results. Parties presenting images, text and material represent they have the rights to do so.
Liquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationPersonalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
More informationCirculating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: 2.04.143 Last Review: 1/2019 Origination: 1/2018 Next Review: 1/2020 Policy Blue Cross and Blue Shield
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationMP Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Medical Policy BCBSA Ref. Policy: 2.04.143 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.121 Miscellaneous Genetic and Molecular Diagnostic Tests 2.04.45 Molecular
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationIntegration of Genomics Into Clinical Pathways. Precision Medicine and Decision Support
Integration of Genomics Into Clinical Pathways Precision Medicine and Decision Support Faculty Andrew Hertler, MD, FACP Chief Medical Officer New Century Health Andrew Hertler, MD, FACP is employed by
More informationECMC cfdna consensus meeting
ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients
More informationLukas Bubendorf Pathologie. Liquid biopsies
Lukas Bubendorf Pathologie Liquid biopsies Liquid biopsies 1. Circulating cell-free tumor-dna (ctdna) 2. Circulating tumor cells (CTC) Source: Sysmex CTCs ctdna ctrna exosomes Quantification Protein RNA
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Page 1 of 36 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Circulating Tumor DNA
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationDr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester
Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationTumor mutational burden and its transition towards the clinic
Tumor mutational burden and its transition towards the clinic G C C A T C A C Wolfram Jochum Institute of Pathology Kantonsspital St.Gallen CH-9007 St.Gallen wolfram.jochum@kssg.ch 30th European Congress
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, the International
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More informationEGFR ctdna Testing. Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester
EGFR ctdna Testing Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester ctdna & EGFR Testing in NSCLC EGFR ctdna testing Non-invasive - patients too sick/biopsy or cytology
More informationMET as a novel treatment target- the story of the sleeping beauty. Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine
MET as a novel treatment target- the story of the sleeping beauty Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine MET as a novel treatment target MET as an oncogene MET
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Tumor Markers for Non-Small Cell Lung Cancer (NSCLC) MP-061-MD-DE Medical Management Provider Notice Date: 10/15/2018;
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationUtility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017
Utility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017 picture placeholder Agenda cobas EGFR Mutation Test v2 Ring Trial SQI Semi Quantitative Index
More informationPositive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
Wang and Chen BMC Cancer (2019) 19:131 https://doi.org/10.1186/s12885-019-5352-7 CASE REPORT Open Access Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationNext-generation sequencing based clinical testing for lung cancer in Japan
Review Article Next-generation sequencing based clinical testing for lung cancer in Japan Masayuki Takeda 1, Kazuko Sakai 2, Kazuhiko Nakagawa 1, Kazuto Nishio 2 1 Department of Medical Oncology, 2 Department
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationTargeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,
More informationRobert Beer
Robert Beer Robert.beer@wales.nhs.uk All Wales Medical Genetics Service Genetic Technologist Training Day 22 nd November 2017 Contents Stratified Medicine NHS EGFR Diagnostic Testing Services Cell free
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationThe Role of Pathology/Molecular Diagnostic in Personalized Medicine
The Role of Pathology/Molecular Diagnostic in Personalized Medicine Ignacio I. Wistuba, M.D. Jay and Lori Eissenberg Professor in Lung Cancer Director of the Thoracic Molecular Pathology Lab Departments
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationDM Seminar. ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat
DM Seminar ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat Introduction Discovery of activating mutations in kinase domain of epidermal growth factor receptor (EGFR) opened a new era of
More informationDiagnostic with alternative sample types (liquid biopsy)
MOLECULAR DIAGNOSTICS OF EGFR AND T790M MUTATIONS CHALLENGES AND SOLUTIONS Diagnostic with alternative sample types (liquid biopsy) James CH Yang, MD, PhD Director, Professor, Graduate Institute of Oncology
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationPathologists role Ancillary Studies in Cytology Challenges. Pre-analytical issues. LUNG CYTOLOGY Predictive markers and molecular tests
Pathologists role LUNG CYTOLOGY Predictive markers and molecular tests Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Pathology Unit, IPATIMUP
More informationKEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl
PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016
More informationCarcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos
Carcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background Immunotherapy
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationDifficult Diagnoses and Controversial Entities in Neoplastic Lung
Difficult Diagnoses and Controversial Entities in Neoplastic Lung Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Chief, Pulmonary Pathology Service Associate Professor, Harvard
More informationLUNG CANCER Searching early biomarkers in blood
LUNG CANCER Searching early biomarkers in blood Eloisa Jantus Lewintre Laboratorio Oncología Molecular- FIHGUV Servicio Oncología Médica, CHGUV Dpto Biotecnología- Universitat Politècnica de València CIBERONC,
More informationMolecular Diagnostics in Lung Cancer
Molecular Diagnostics in Lung Cancer Mutations in lung carcinomas and their impact on diagnosis and treatment With special thanks to: Barbara Chaitin, MD Medical Director, Esoteric Services AmeriPath Orlando,
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Molecular Tumor Markers for Non-Small Cell Lung Cancer (NSCLC) NMP206 Effective Date*: November 2010 Update: June 2016 This National Medical Policy is subject
More informationEnterprise Interest Thermo Fisher Scientific / Employee
Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical
More informationCirculating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: Original Effective Date: MM.02.044 10/01/2018 Line(s) of Business: Current Effective Date Section: 10/01/2018
More informationCase Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationDiagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
More informationTransforming Oncology With Precision Medicine Solutions. Company Overview January 2017
Transforming Oncology With Precision Medicine Solutions Company Overview January 2017 FORWARD-LOOKING STATEMENTS Statements in this presentation about the Company's expectations, applications of its technology,
More informationStephen Finn University of Dublin Trinity College and St. James s Hospital, Dublin, Ireland
Evaluation of NGS and other methods for ALK translocation detection in NSCLC patients in Europe: results of the European Thoracic Oncology Platform (ETOP) Lungscape Project Stephen Finn University of Dublin
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationCLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases
CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases Adriana Muniz 1, Mariko Matsutani 1, Karena Kosco 1, John Spinosa 1, Cecile
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationComprehensive genomic profiling for various solid tumors
Content Highlight Test Specification Test Content Performance Validation Test Report I II III IV V The NovoPM TM comprehensive cancer genomic profiling test Comprehensive genomic profiling for various
More informationMolecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA
Molecular Pathology and Lung Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA aiafrate@partners.org Disclosures Preliminary patent application NGS AMP Fusion
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationA complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis
APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown
More informationAgenda. What is a Liquid Biopsy? Biocept technology. Concordance With Tissue. Clinical Applications. Billing and Reimbursement.
Agenda What is a Liquid Biopsy? Biocept technology Concordance With Tissue Clinical Applications Billing and Reimbursement Recap & Questions 1 Targets of Tumor Found in Liquid Biopsy 1 Eric Topol, Professor
More informationOncomine Focus assay panel and Oncomine Knowledgebase Reporter.
Oncomine Focus assay panel and Oncomine Knowledgebase Reporter. How it can help to identify relevant alteration and early phase trials. Dr Isabelle SOUBEYRAN Dr Emmanuel KHALIFA Molecular Pathology Unit
More informationCirculating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: 2.04.143 Last Review: 1/2018 Origination: 1/2018 Next Review: 1/2019 Policy Blue Cross and Blue Shield
More informationCirculating tumor DNA detection in advanced non-small cell lung cancer patients
Original Article Circulating tumor DNA detection in advanced non-small cell lung cancer patients Zhi-Wei Guo 1 *, Min Li 1 *, Ji-Qiang Li 2, Chun-Lian Zhou 1, Xiang-Ming Zhai 1, Ming Li 1, Ying-Song Wu
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More information